7 recruiting, 4 completed, 2 active not recruiting, 2 unknown. 8 Phase 2, 4 Phase 1, 2 Early Phase 1, 2 Not applicable, 2 Phase 3.
Follow Alveolar Soft Part Sarcoma: new trials by email Literature Review of Alveolar Soft Part Sarcoma trials Research Report on Alveolar Soft Part Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-10-16 |
| Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma Benmelstobart injection combined with Anlotinib hydrochloride capsule - Alveolar Soft Part Sarcoma | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 33 | 2026-04-02 | 2026-04-23 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) GCAR1 - Alveolar Soft Part Sarcoma | Early Phase 1 | Active not recruiting | AHS Cancer Control Alberta | 1 | 2024-02-01 | 2026-03-23 |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma GCAR1 - Alveolar Soft Part Sarcoma | Early Phase 1 | Completed | AHS Cancer Control Alberta | 1 | 2023-09-06 | 2025-07-23 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Patient with Soft Tissue Sarcoma - Soft Tissue Sarcoma, Clear Cell Sarcoma | Not applicable | Recruiting | Institut Claudius Regaud | 400 | 2021-04-26 | 2026-02-10 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 | |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) GB226 - Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Genor Biopharma Co., Ltd. | 35 | 2018-09-06 | 2021-03-03 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Hypofractionated radiotherapy, Hyperthermia - Sarcoma, Alveolar Soft Part Sarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 30 | 2018-06-01 | 2021-02-01 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Axitinib, Pembrolizumab - Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas | Phase 2 | Completed | Jonathan Trent, MD, PhD | 33 | 2016-04-19 | 2024-07-12 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research Alveolar Soft Part Sarcoma, Sarcoma | Completed | National Cancer Institute (NCI) | 99999 | 2005-04-07 | 2017-07-02 |
Sarcoma, Alveolar Soft Part (17) · Sarcoma (11) · Sarcoma, Clear Cell (6) · Sarcoma, Synovial (5) · Histiocytoma, Malignant Fibrous (4) · Leiomyosarcoma (4) · Liposarcoma (4) · Neurofibrosarcoma (4) · Dermatofibrosarcoma (3) · Fibrosarcoma (3) · Sarcoma, Ewing (3) · Carcinoma, Renal Cell (2) · Chondrosarcoma, Extraskeletal Myxoid (2) · Desmoplastic Small Round Cell Tumor (2) · Nerve Sheath Neoplasms (2)
Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms, Muscle Tissue (17) · Neoplasms, Connective Tissue (9) · Neoplasms, Nerve Tissue (6) · Nervous System Diseases (6) · Nervous System Neoplasms (6) · Sarcoma (6) · Neoplasms, Fibrous Tissue (5) · Neuromuscular Diseases (5) · Peripheral Nervous System Diseases (5) · Peripheral Nervous System Neoplasms (5) · Histiocytoma (4) · Neoplasms by Site (4)
pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide (1) · Axitinib (1) · Bevacizumab (1) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Dacarbazine (1) · Dactinomycin (1) · Diathermy (1) · Digoxin (1) · Doxorubicin (1) · Fluorouracil (1)
National Cancer Institute (NCI) (3) · AHS Cancer Control Alberta (2) · Advenchen Laboratories, LLC (1) · Canadian Cancer Trials Group (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · ECOG-ACRIN Cancer Research Group (1) · Genor Biopharma Co., Ltd. (1) · Institut Claudius Regaud (1) · Jonathan Trent, MD, PhD (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Matthew Ingham (1) · Memorial Sloan Kettering Cancer Center (1) · Taiho Pharmaceutical Co., Ltd. (1) · University of Florida (1)
United States (8) · Canada (4) · China (3) · France (1) · Italy (1) · Japan (1) · Poland (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1)
Aaron R Weiss (1) · Edmund Bartlett, MD (1) · Jonathan C Trent, MD (1) · Jordan Milner, MD (1) · Kenneth Cardona (1) · Matthew Ingham, MD (1) · Michael Dean, Ph.D. (1) · Mona Shafey (1) · Mona Shafey, MD, FRCPC (1) · Srivandana Akshintala (1) · Yuankai Shi, Doctor (1)
PMID 31078463, PMID 31401903, PMID 32702309, PMID 32827353, PMID 34515544, PMID 34722269, PMID 37523624
U10CA180886 (2), U10CA098543 (1), U10CA180830 (1), UG1CA189828 (1)